Table 1.
Association of CTC (<5 versus ⩾5) with clinical pathological variables.
| CTC | |||
|---|---|---|---|
| <5 (n = 310) | ⩾5 (n = 206) | p 1 | |
| No. (%) | No. (%) | ||
| Age, median value (range) | 48 (25–81) | 49 (23–81) | 0.2072 |
| Histology | |||
| Ductal | 267 (87.2) | 164 (79.6) | |
| Nonductal | 43 (12.8) | 42 (20.4) | 0.330 |
| Hormone receptor status | |||
| ER negative | 121 (39.0) | 64 (31.1) | |
| ER positive | 189 (61.0) | 142 (68.9) | 0.065 |
| HER2 status | |||
| Negative | 244 (79.0) | 170 (82.9) | |
| Positive | 65 (21.0) | 35 (17.1) | 0.267 |
| Unknown | 1 | 1 | |
| Tumor subtype | |||
| Triple-negative | 82 (27.1) | 42 (20.9) | |
| HER2+ | 65 (21.4) | 35 (17.4) | |
| HER2– ER+ | 156 (51.5) | 124 (61.7) | 0.032 |
| Unknown or missing data | 7 | 5 | |
| Number of metastatic sites | |||
| 1 | 104 (33.5) | 49 (23.8) | |
| 2 | 93 (30.0) | 59 (28.6) | |
| ⩾3 | 113 (36.5) | 98 (47.6) | 0.005 |
| Metastatic site | |||
| Visceral | 188 (60.6) | 131 (63.6) | |
| Nonvisceral | 122 (39.4) | 375 (36.4) | 0.500 |
| Number of chemotherapeutic line | |||
| First-line | 95 (46.3) | 70 (46.7) | |
| Second-line | 54 (26.4) | 29 (19.3) | |
| Third-line or more | 56 (27.3) | 51 (34.0) | 0.492 |
| Number of hormotherapeutic line | |||
| First-line | 33 (47.1) | 14 (43.7) | |
| Second-line | 14 (20.0) | 8 (25.0) | |
| Third-line or more | 23 (32.9) | 10 (31.3) | 0.924 |
| Number of anti-HER2 treatment line | |||
| First-line | 15 (45.5) | 13 (59.1) | |
| Second-line | 10 (30.3) | 2 (9.1) | |
| Third-line or more | 8 (24.2) | 7 (31.8) | 0.798 |
| NLR | |||
| <3 | 179 (57.7) | 107 (51.9) | |
| ⩾3 | 131 (42.3) | 99 (48.1) | 0.195 |
| PLR | |||
| <210 | 173 (55.8) | 120 (58.2) | |
| ⩾210 | 137 (44.2) | 86 (41.8) | 0.583 |
| SII | |||
| <836 | 184 (59.3) | 116 (56.3) | |
| ⩾836 | 126 (40.7) | 90 (43.7) | 0.493 |
| MLR | |||
| <0.34 | 158 (51.0) | 95 (46.1) | |
| ⩾0.34 | 152 (49.0) | 111 (53.9) | 0.281 |
1
Chi-square test.
2
Median test.
ER, estrogen receptor; MLR, monocyte–lymphocyte ratio; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic immune-inflammation index.